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ABSTRACT 
    Epstein-Barr virus (EBV) is a human gamma-herpes virus that colonized more than 
90% of the adult population. The virus is able to infect and immortalize B lymphocytes 
both in vitro and in vivo. Despite of the mostly harmless outcome of the EBV infection, 
EBV is associated with a number of malignancies, such as Burkitt lymphoma, classical 
Hodgkin lymphoma, and Diffuse large B-cell lymphoma (DLBCL). 
    DLBCLs, the most common group of malignant lymphomas, account for 30% of 
adult non-Hodgkin lymphomas (NHLs). EBV-positive DLBCL of the elderly is a 
newly recognized subtype of DLBCL which accounts for 8% to 10% of DLBCL in 
Asian countries, but seems to be less common in Western populations. 
    In this study we have characterized EBV-positive DLBCL cell lines by checking 
EBV latent gene and cellular gene expression. Then, we studied the modulation of EBV 
latent gene and cellular gene and the EBV modulated chemotaxis in the EBV-positive 
DLBCL lines upon cytokine treatment. We found that IL-4 and IL-21 upregulated 
LMP1 expression in EBV-positive DLBCL lines and IL-21 downregulated EBNA2 and 
EBNA1 expression in the type III line, Farage. IL-4 and IL-21 were found to induce 
different patterns of CXCR4 or CCR7 mediated chemotaxis in DLBCL lines. We also 
knocked out EBV from EBV-positive DLBCL lines and found that EBV provided 
survival factors to these lines. We further studied modulation of chemotaxis after 
downregulation of EBV encoded genes by dominant negative EBNA1 (dnEBNA1) in 
DLBCL cells upon cytokine treatment and observed decreased chemotaxis mediated by 
CXCR4 or CCR7 upon IL-4 or IL-21 treatment. 
    As IL-21was reported to induce apoptosis in DLBCL lines with unknown EBV 
status, we also examined the IL-21 sensitivity of the EBV positive type III DLBCL 
line, Farage, and found surprisingly that despite c-Myc upregulation, IL-21 induced cell 
proliferation rather than apoptosis. EBV knock-out counteracted the IL-21 induced 
proliferation of Farage and increased apoptosis. This finding reveals a previously 
unknown role of EBV in DLBCL that is of possible relevance for the current attempt to 
use IL-21 in therapy.  
    Studies on the EBV modulated chemotaxis after EBV infection on tonsillar B cells 
found downregulation of CXCR5 and CCR7 mediated chemotactic responses, which 
are important for migration into lymphoid tissue. These alterations may lead to 
retention of EBV-infected tonsillar B cells in the interfollicular region of the tonsil. 
    Further work on type I interferons (IFNs) identified their role in upregulation of 
LMP1 expression by direct activation of the ED-L1 promoter in several EBV-carrying 
Burkitt's lymphoma lines. In EBV-infected primary B cells, IFN-α transiently 
upregulated LMP1 mRNA, but not protein levels, followed by downregulation of both, 
suggesting a novel antiproliferative mechanism of type I IFNs.  
    Altogether our results not only provide evidence for the important roles of 
microenvironmental stimulation in EBV-carrying B cells but might also have future 
therapeutic implications.  
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1 INTRODUCTION 
1.1 EBV general introduction 
Epstein-Barr virus (EBV) is a human gamma-herpes virus of the Lymphocryptovirus 
(LCV) genus that colonized more than 90% of the adult population. As a member of 
this genus, EBV is able to infect and immortalize B lymphocytes both in vitro and in 
vivo. 
 
EBV was first discovered in a B cell derived lymphoma, Burkitt lymphoma (BL), 
named after its discoverer, Dennis Burkitt, with characteristic epidemiological, clinical 
and histopathological features (Burkitt, 1958; Epstein et al., 1964). The in vitro 
transforming capacity of this virus for B lymphocytes was identified soon after its 
discovery (Henle et al., 1967; Pope et al., 1968). This in vitro transformation system 
was widely used to investigate the viral transforming mechanism and the immune 
response against the virus carrying cells. The in vitro virus induced proliferation was 
considered as strong evidence for a similar mechanism in the development of BL. 
However the presence of EBV negative BL lymphomas that showed similar pathology 
and identical cytogenetical changes revealed that the virus alone might not be 
responsible, but possibly plays a role in the development of BL.  
 
The primary EBV infection generally occurs during early childhood and is normally 
asymptomatic. The delayed primary infection in about half of the adult individuals can 
result in a benign, self-limiting disease called infectious mononucleosis (IM) (Klein et 
al., 2007). This disease is also frequently referred to as kissing disease. The symptoms 
of IM are the immune response, the atypical lymphocytosis which is made up by virus 
specific CD8
+
 and CD4
+
 T lymphocytes. IM can be easily diagnosed by detection of 
IgM antibodies against the virus capsid antigen (VCA). Antibodies against EBV 
encoded proteins associated with lytic and latent infection can be detected in a 
sequential manner. The presence of EBV can also be detected in the saliva, in in vitro 
established lymphoblastoid cell lines (LCLs) and in the peripheral blood mononuclear 
cells (PBMC) by PCR techniques.  
 
Despite of the mostly harmless outcome of the EBV infection, it is important to note 
that certain immuno-deficient patients can not control the infection and develop fatal 
IM. X-linked lymphoproliferative disease (XLP) is the prominent example of this state 
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(Bassiri et al., 2008; Seemayer et al., 1995). This disease is due to the mutations in the 
SH2D1A (SAP) gene (Coffey et al., 1998; Nichols et al., 1998; Sayos et al., 1998). 
However, XLP patients can control infections caused by other viruses. Interestingly, 
EBV was not reported to cause disease in patients that HSV-1 causes encephalitis due 
to altered IFN-pathway (Zhang et al., 2008).  
 
 
  Figure 1. Diagram showing the structure of EBV (Adapted from CULLEN LAB) 
 
 
1.2 EBV latent gene expression 
1.2.1 The type III latency 
EBV establishes a latent infection and imposes the continuous B lymphocyte 
proliferation, giving rise to LCLs upon in vitro infection. In such LCL cells one of the 
two viral promoters (Cp or Wp) is used to generate a polystronic mRNA. This mRNA 
can be spliced into the mRNA of six nuclear proteins (EBV nuclear antigen: EBNA1-6, 
also called EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA-LP and EBNA3C). 
Additionally, three membrane proteins i.e. Latent Membrane Protein (LMP) 1, 2A and 
2B are expressed as well. This latent gene expression pattern is termed type III latency. 
Except for these proteins, type III latent cells express three sets of EBV non-coding 
Epstein-Barr virus  
 
Family: Herpesviridae (dsDNA) 
Genus: Lymphocryptovirus  
Species: Human herpesvirus 4 (HHV-4) 
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RNAs: EBER1 and EBER2, BARTs, EBV microRNAs (miRNAs). EBERs are 
considered to be expressed in all EBV carrying cells including both normal and 
malignant cells where the virus is maintained in a latent state. Furthermore, 24 hours 
after EBV infection, two Bcl-2 homologs (BALF1 and BHRF1) are expressed by B 
cells (Altmann and Hammerschmidt, 2005).   
     
The circular EBV genome in the virus carrying cells is maintained as an extra-
chromosomally replicating episome. EBNA1 is pivotal for the replication and 
partitioning of the virus genomes during cell division as it binds to the origin of virus 
genome and tethers the episome to the chromosomes during mitosis. However, the 
function of EBNA1 is not perfect and EBV genomes are shown to be lost during 
replication (Altmann et al., 2006). In addition to tethering the viral episome to the 
chromosome, the anti-apoptotic role of EBNA1 in EBV carrying malignant cells was 
also reported (Kennedy et al., 2003). 
      
Additionally, the two Bcl-2 homologs (BALF1 and BHRF1) and EBER2 were found to 
play important role in the virus induced B cell growth transformation (Nichols et al., 
1998; Wu et al., 2007). It’s been shown recently that although germinal center (GC) B 
cells could be transformed in vitro with a recombinant EBV encoding a conditional, 
floxed LMP2A allele, their survival and continued proliferation were dependent on 
LMP2A (Mancao and Hammerschmidt, 2007). 
 
EBNA2 is instrumental for type III latency for it activates LMP1, LMP2 and Cp viral 
promoters in B cells (Eliopoulos and Young, 2001; Izumi and Kieff, 1997). It does not 
bind directly to DNA but acts as a trans-activator through interactions with other DNA-
binding proteins (Coope et al., 2002; Dillner et al., 1985; Eliopoulos and Young, 2001; 
Gires et al., 1997; Huen et al., 1995; Kaykas et al., 2001; Lam and Sugden, 2003). 
EBNA2 hijacks the Jκ recombination signal-binding protein RBP-jκ (also known as 
CBF-1) which is the major transcription factor of the Notch pathway (Dawson et al., 
2003; Eliopoulos et al., 2003; Eliopoulos and Young, 1998; Mosialos et al., 1995). 
EBNA2 can also interact with PU.1 and the ATF-2/c-Jun heterodimers (Fahraeus et al., 
1990; Li and Chang, 2003; Tsao et al., 2002). 
 
EBV carrying type III latent cells are also observed in the lymphoid tissues of IM 
patients, tonsillar B cells of healthy EBV carrying individuals, post-transplant 
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lymphoproliferative disease (PTLD) patients and lymphomas in AIDS patients. Due to 
their high immunogenicity the type III cells in the first two examples only survive and 
proliferate transiently, as they are recognized and killed by cytotoxic T-lymphocytes 
(CTLs) (Dawson et al., 1990). However in the last two situations they survive and 
proliferate because of the lack of CTL control.  
 
LMP1 is a transmembrane protein with an intracellular terminus followed by six 
membrane-spanning domains, and an intracellular carboxyl-terminal domain 
(Eliopoulos and Young, 2001; Lam and Sugden, 2003). It signals in a constitutive 
active manner and self-aggregation is needed for its signaling capacity (Gires et al., 
1997). Additionally, LMP1 is located on the lipid rafts and this localization is important 
for its signaling capacity (Kaykas et al., 2001). 
 
Table 1. EBV latent gene expression patterns in EBV associated malignancies 
 
BL-Burkitt lymphoma, PEL-primary effusion lymphoma, NPC-nasopharyngeal carcinoma, GC-
gastric carcinoma, PTLD-post transplant lymphoproliferative disorders, cHL-classical Hodgkin 
lymphoma 
 
 
As a viral mimic of CD40 LMP1 is a glycoprotein belonging to the tumor necrosis 
factor receptor (TNFR) family. By binding to TNFR associated factors (TRAF) and/or 
TNFR associated death domain-containing protein (TRADD) LMP1 activates both the 
classical and non-classical NF-κB, stress-activated MAP kinase, phosphatidylinositol 3 
kinase and extracellular regulated kinase (ERK)-MAPK signaling pathways (Coope et 
al., 2002; Dawson et al., 2003; Eliopoulos et al., 2003; Eliopoulos and Young, 1998; 
Huen et al., 1995; Izumi and Kieff, 1997; Mosialos et al., 1995). LMP1 induces 
 EBV latent gene expression Promoter  Associated malignancies 
Type I EBNA1 Qp BL, NPC, PTLD, PEL 
Type II EBNA1, LMP1, LMP2A, 
LMP2B 
Qp cHL, NK/T, NPC, PTLD, 
GC 
Type IIB EBNA1~6 Cp PTLD 
Type III EBNA1~6, LMP1, LMP2A, 
LMP2B 
Cp PTLD, DLBCL 
Wp-restricted EBNA1, 3, 4, 5, 6 Wp Wp-restricted BLs 
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multiple gene expression involved in anti-apoptosis, cytokines, adhesion and activation 
markers and tumor metastasis (Li and Chang, 2003). LMP1 also represses certain genes 
in an indirect manner e.g. the repression of E-cadherin through the induction of 
DNMT1 and the downregulation of BCL6 possibly via induction of IRF4. 
Additionally, it is important to notice that the effect of LMP1 and the signaling 
pathways involved have certain tissue specificity.  
 
As the major EBV encoded transforming protein, LMP1 behaves as a classical 
oncogenic protein in rodent fibroblast transformation assays (Tsao et al., 2002). 
Additionally, in monolayer keratinocytes LMP1 inhibits cell differentiation of 
immortalized epithelial cells in raft cultures, alters cell morphology and cytokeratin 
expression whereas it induces epidermal hyperplasia when expressed in the skin of 
transgenic mice (Dawson et al., 1990; Fahraeus et al., 1990; Tsao et al., 2002; Wilson 
et al., 1990).  
 
Previous studies showed that LMP1 is not only required for efficient immortalization of 
the B lymphocytes in vitro but also important for B cell proliferation (Dirmeier et al., 
2005; Kaye et al., 1993; Kilger et al., 1998). LMP1 expression in transgenic mice 
resulted in an increased incidence of lymphomas especially at old age (Kulwichit et al., 
1998). Furthermore, the inhibition of GC formation was observed in mouse 
backgrounds (Uchida et al., 1999). 
 
In vitro study showed that LMP1 inhibited the proliferation of BL lines when expressed 
in an inducible manner (Floettmann et al., 1996). This effect might be due to inhibition 
of BCL6 which is known to be crucial to the proliferation of BL cells (Phan and Dalla-
Favera, 2004; Phan et al., 2005). 
 
LMP2A and LMP2B are transmembrane proteins containing 12 membrane spanning 
domains. The difference between LMP2A and LMP2B lies in the first exon that 
encodes a signaling domain which is part of LMP2A, but is absent in LMP2B (Alber et 
al., 1993). Expression of LMP2A or LMP2B in the epithelial cell lines A431, SCC12F 
and HaCaT was found to enhance their capacity to migrate and spread on extracellular 
matrix (Allen et al., 2005).  
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Figure 2. The EBV genome (Adapted from Young et al., Nature Reviews Cancer 
2004) a) Electron micrograph of the Epstein–Barr virus (EBV) virion. b) Diagram showing the 
location and transcription of the EBV latent genes on the double-stranded viral DNA episome. c) 
Location of open reading frames for the EBV latent proteins on the BamHI restriction-endonuclease 
map of the prototype B95.8 genome. 
 
1.2.2 The type II latency 
This EBV gene expression pattern was first observed in nasopharyngeal carcinoma 
(NPC) with the expression of EBNA1, LMP1 and LMP2 (Fahraeus et al., 1988a; Rowe 
et al., 1992; Young et al., 1988). The typical malignancies associated with type II EBV 
gene expression are the classical Hodgkin lymphoma, EBV positive T cell lymphoma, 
NK lymphoma and some NPCs (Chen et al., 1993; Chiang et al., 1996a; Deacon et al., 
1993; Minarovits et al., 1994; Niedobitek et al., 1991; Pallesen et al., 1991). Except for 
cHLs, there are sporadic reports form literatures describing B cell originated 
malignancies with this EBV gene expression pattern.  
   7 
 
It is important to note that although the encoded proteins are identical the structure of 
the EBNA1 mRNA originated from the Cp/Wp or Qp is different (Nonkwelo et al., 
1996; Schaefer et al., 1995; Tsai et al., 1995). Additionally, since EBNA2 is not 
expressed in type II latency, other cellular or viral proteins must be involved in the 
induction of the expression of LMP1 and LMP2 with unknown mechanism. 
 
1.2.3 The type I latency 
In the type I latent gene expression pattern only EBNA1 is expressed and its expression 
is driven by the Op and includes the Q, U, and K exons. The classical example of type I 
EBV latent gene expression is the endemic BLs (Rowe et al., 1987). In addition, all 
EBV carrying primary effusion lymphomas (PELs) (Horenstein et al., 1997), some 
PTLDs (Capello et al., 2003) and NPCs express type I latency. 
 
1.2.4 The type IIB latency 
In B-CLL cells infected with EBV in vitro all the 6 nuclear proteins (EBNA1-6) are 
expressed without the expression of LMP1. This type of EBV latent gene expression 
pattern is termed type IIB latency (Klein et al., 2007; Klein et al., 2006). When in vitro 
EBV infected B-CLL cells grow out occasionally long after infection (termed CLL-
LCLs), they express LMP1 (Klein et al., 2007). This is consistent with the requirement 
of LMP1 for B cell immortalization. EBV positive cells expressing type IIB latency 
were not only found in the in vitro infected B-CLL cells, but also in the PTLD patients 
(Kurth et al., 2003), in the lymphoid tissues of IM patients (Kurth et al., 2003) and in 
the EBV infected humanized mice (Cocco et al., 2008).   
 
1.2.5 The Wp restricted latency 
This viral gene expression pattern was first observed in the BL lines P3HR1 and Daudi 
(Altiok et al., 1992; Woisetschlaeger et al., 1990) and later found in some primary 
endemic BLs (Kelly et al., 2002). In these cases the viral genomes have deletion in the 
EBNA2 gene and do not express the type I pattern. Instead, the Wp promoter is used to 
generate the primary RNA from which EBNA5,3,4,6,1 are spliced (Kelly et al., 2002). 
Since EBNA5 gene is located in the vicinity of EBNA2 it is truncated and its size 
depends on the size of deletion (Kelly et al., 2002).  
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1.3 EBV in normal B cells 
It is clarified today that EBV establishes a life long infection in the class-switched 
memory B cell reservoir (Babcock et al., 1998). The virus is believed to be re-activated 
upon plasma cell differentiation and produce new progeny that are shed in the saliva 
(Thorley-Lawson, 2005). The theories about how EBV accesses the memory B cell 
pool will be discussed below.  
 
Early work found that differ from the EBV latent gene expression pattern seen in LCLs 
EBV carrying B cells in the peripheral blood B cells only express EBNA1, LMP2 and 
EBERs (Chen et al., 1995; Qu and Rowe, 1992; Tierney et al., 1994). These EBV 
carrying memory B cells isolated from PBMC did not express LMP1 mRNAs and only 
rarely expressed LMP2 mRNAs and consequently shown to express a type I/0 latent 
gene expression pattern. 
 
In the peripheral blood the frequency of EBV-carrying B cells is 1-50/10
6
 B cells and 
the frequency is stable over time for at least 1-3.5 years (Khan et al., 1996). The 
frequency of EBV infected cells in IM patients can range from 1 in every 2 memory B 
cells to 1 in over 100 memory B cells (Hochberg et al., 2004). This frequency in IM 
patients can be 1000 fold higher than in healthy carriers. Just as in the healthy EBV 
carriers, EBV infection in the blood of IM patients is tightly regulated as the phenotype 
of latently infected cells is restricted to CD20+, CD27+, sIg+, IgD- and CD5 
(Hochberg et al., 2004).  
 
Type III B cells were found in healthy carriers during primary infection (Kurth et al., 
2000; Niedobitek et al., 1997a) and the virus carrier state (Joseph et al., 2000) which is 
similar to the EBV latent gene expression observed in LCLs. Due to the high 
immunogenicity of these type III cells, they are eliminated by the emerging cellular 
immune responses (Hislop et al., 2007). 
 
It was reported that in one of the studies performed on FACS-sorted tonsillar B cell 
subpopulations the type III latent B cells specifically segregated within the naive B cell 
population (Babcock et al., 2000). In the same study EBV carrying GC B cells 
expressed type II latency which is similar to the virus carrying memory B cells from the 
same tonsils (Babcock et al., 2000). 
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The lytic induction of EBV infection is mediated by the immediate-early proteins 
BZLF1 and BRLF1 (Amon and Farrell, 2005). Both players are transcription factors 
that can activate each other’s transcription. These two proteins together are sufficient to 
initiate the entire lytic gene expression cascade. The activation of their promoters by 
cellular transcription factors is the crucial initial step for lytic cycle induction because 
in latently infected cells the promoters of BZLF1 and BRLF1 are inactive. BCR 
engagement can activate EBV lytic gene expression in some B cell lines and the 
immediate early EBV promoters in reporter gene assays as well (Amon and Farrell, 
2005). 
 
It has been shown that differentiation into PC initiates viral replication as the FACS 
sorted CD38-high, CD10-, CD19+ CD20-low, surface Ig- and cytoplasmic Ig+ PC in 
the tonsils of healthy carriers EBV latent gene expression switched to the lytic 
replication (Laichalk and Thorley-Lawson, 2005). Two later studies supported this 
finding that the plasma cell specific transcription factor XBP-1 binds to and 
transactivates the promoter of BZLF1 (Bhende et al., 2007; Sun and Thorley-Lawson, 
2007). 
 
1.3.1 Thorley-Lawson’s model 
Based on the above studies, Thorley-Lawson has developed a model to explain how 
EBV accesses the memory B cell pool (Thorley-Lawson, 2001, 2005). In this model 
naïve B cells are infected with EBV and express the type III latency. Due to the high 
immunogenicity these cells are recognized and eliminated by the cellular immune 
response in healthy EBV carriers. EBV carrying B cells which escaped from the 
immune responses then enter and differentiate in the GCs of secondary follicles into 
GC B cells. The EBV gene expression in these cells is concomitantly switched to type 
II (also referred to as the “default program”). The LMPs are proposed to provide the 
signals for the survival and differentiation of type II latent GC B cells as LMP1 mimics 
the CD40 and LMP2 mimics the BCR signaling.   
 
This model further proposed that when the EBV positive B cells leave the GC 
microenvironment the EBV encoded proteins would be downregulated. In the resting 
memory B cells only the EBERs are detectable, EBNA1 expression is induced when 
the cells become activated and enter cell cycle. EBV lytic cycle will be initiated and 
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new virus will be produced in the saliva upon PC differentiation of EBV carrying 
memory B cells, helping in transmission of the virus. 
 
 
 
Figure 3. Thorley-Lawson’s model of how EBV establishes and maintains 
persistent infection （Adapted from Thorley-Lawson et al., Nat Rev Microbiol. 
2008） 
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Based on the similarity in EBV latent gene expression pattern between the EBV-
carrying normal B cells at different differentiation stages and the EBV carrying B cell 
lymphomas Thorley-Lawson also proposed that one can pinpoint the precursors of the 
lymphomas (Thorley-Lawson, 2005). He proposed in his theory that EBV positive BLs 
might have arisen from memory B cells as they express type I latency and type I 
latency was only found in EBV-carrying normal memory B cells. He also concluded 
that HRS cells arose from the type II GC B cells as cHLs express type II latency and 
similar EBV gene expression pattern could be found in GC B cells. However, this 
simplistic theory might not reveal the precursors of EBV-carrying B cell derived 
malignancies as the viral gene expression can be modulated by the microenvironment 
or during the transformation process. 
 
1.3.2 Kuppers’ model  
The study of micro-dissected EBV-carrying GC B cells from the tonsils of IM patients 
and the SHM of their rearranged Ig V genes revealed that most of the EBV-carrying 
GC B cells belonged to clones of B cells harboring somatically mutated Ig V gene 
rearrangements but not the ongoing SHM, the hallmark of the GC reaction (Kurth et al., 
2003; Kurth et al., 2000). Based on these findings Kuppers has developed another 
model. In this model EBV infects the GC or memory B cells directly without the 
requirement of GC differentiation of the EBV-carrying naïve B cells (Kuppers, 2003; 
Kurth et al., 2003; Kurth et al., 2000). This model is also referred to as the GC-
independent model. This model is further supported by two studies on EBV persistence 
in immuno-deficient patients whose B cells can not undergo normal GC differentiation 
and consequently lack class-switched memory B cells (Chaganti et al., 2008; Conacher 
et al., 2005). 
 
To sum up, both models have their own strength and weakness. Today, the mechanism 
how EBV accesses the memory B cell pool is still not fully clarified. 
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Figure 4. Kuppers’ model of how EBV establishes and maintains persistent 
infection （Adapted from Kuppers, Nat Rev Immunol. 2003） 
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1.4 EBV in tumors 
1.4.1 Burkitt lymphoma 
The immunophenotype of BL resembles GC B cells as they are found to be IgM+, 
CD20+, CD10+, BCL6+ and BCL2-. Their genotype is characterized by rearranged Ig 
genes with SHMs in the V regions and the structure of Ig-myc translocation. Based on 
these findings BL cells are considered to be originated from GC B cells and arrested in 
their differentiation stage at this stage (Bornkamm, 2009; Thorley-Lawson and Allday, 
2008). It seems that c-myc expression in BL is ectopic as GC B cells do not express c-
myc (Klein et al., 2003). The driving force for the proliferation of BL cells is the 
constitutive activation of c-myc, a result of chromosomal translocation between 
chromosome 8 and either chromosome 2, 14 or 22 (Bornkamm, 2009; Thorley-Lawson 
and Allday, 2008). 
 
Three clinical variants of BL are defined based on morphology, biology and clinical 
features: the sporadic BL, the endemic BL and the AIDS-associated BL. EBV is 
observed in 30% of sporadic BL, in 25-40% of AIDS-BL and in almost all endemic 
BLs (Rowe et al., 1987) (Table 2). The EBV gene expression in BLs is heterogeneous 
as most of the EBV carrying BLs are type I whereas some other BLs were observed to 
be either type II or the “Wp-restricted” (Araujo et al., 1996; Niedobitek et al., 1995). 
 
Initially, type I gene expression in BL was considered to be the result of immune 
selection in vivo as the cells would have been cleared by the EBV specific cytotoxic T 
cells. However, this theory was proven to be incorrect as BLs are more common in HIV 
infected patients with type I latency than in other types of immunosuppressive patients. 
 
It was shown that EBV negative BL cells (mostly sporadic BL) had lower numbers of 
somatic hyper mutations in their Ig heavy chain genes compared to EBV positive BL 
cells (mostly endemic and HIV associated BL) which suggested that EBV negative BLs 
might be derived from early centroblasts whereas EBV positive cases might be 
originated from late or post-germinal center B cells (Bellan et al., 2005). 
 
Although the type I EBV gene expression in BL is not associated with induction of 
proliferation, making it difficult to understand EBV’s contribution to the genesis of BL, 
EBV encoded latent genes might contribute to the development of cancer cells through 
other mechanisms such as induction of genomic instability, inhibition of apoptosis and 
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inhibition of DNA repair. Previous studies showed that EBNA1 and EBERs are anti-
apoptotic in vitro (Kennedy et al., 2003; Komano et al., 1999). EBNA1 was reported to 
induce genomic instability in vitro. Inhibition of the function of EBNA1 by dominant 
negative EBNA1 decreased proliferation of both type I and Wp-restricted BL lines 
(Kennedy et al., 2003; Nasimuzzaman et al., 2005; Watanabe et al., 2010). The anti-
apoptotic function of EBV might counteract the pro-apoptotic effect of the aberrantly 
expressed c-myc in the BL   
 
1.4.2 Classical Hodgkin lymphoma 
In the Classical Hodgkin lymphoma (cHL) the characteristic mononuclear Hodgkin and 
multinucleated Reed-Sternberg (HRS) cells is only about 1%, surrounded by non-
neoplastic, inflammatory cells. The Ig gene rearrangements indicate that most of the 
HRS cells are derived from B cells (Kuppers et al., 2003). HRS cells are considered to 
be derived from pre-apoptotic GC B cells as they carry high load of SHM in the IgV 
genes. Aberrant activation of the NF-kB and JAK-STAT pathways are believed to 
contribute to the survival of HRS cells (Kuppers, 2009).   
 
Depending on the histological subtype, geographical distribution and the status of the 
patient the frequency of the EBV positive HLs varies from 40% to 100% (Herbst, 
1996). The EBV latent gene expression in HRS cells is type II. While the EBV carrying 
HRS cells always express LMP1, the expression of LMP2A was observed only in 52%-
90% of the cases (Natkunam et al., 2007; Niedobitek et al., 1997b). Since LMP1 and 
LMP2A are considered to provide survival signals to B-lymphocytes by mimicking the 
CD40 and BCR pathways respectively, it was believed that in the EBV positive cHLs 
expression of these proteins could be responsible for the survival of the HRS 
precursors. EBV regulated genes such as autotoxin, Bmi1 and CCL20 also play an 
important role in the transformation and survival of HRS precursors (Baumforth et al., 
2008; Baumforth et al., 2005; Dutton et al., 2007). 
 
HRS cells are dependent on the survival signals from the microenvironment as they are 
difficult to grow in culture and in immunodeficient mice and they are rarely found in 
the peripheral blood (Kuppers, 2009). 
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1.4.3 NK and T cell lymphoma 
EBV is also observed in the aggressive NK cell leukemias, the EBV positive T cell 
lymphoproliferations of childhood and the extranodal NK/T cell lymphomas.  
 
The extranodal NK/T cell lymphomas found mostly in Asians and Native Americans in 
central and South America are basically always EBV positive (Aozasa et al., 2008; 
Nava and Jaffe, 2005). These tumors are termed “NK/T” in order to include the 
malignancies of both NK and T cell origin as most of the cases genotypically resemble 
NK cells whereas some are likely to be originated from CTL. Since these tumor cells 
express EBNA1, LMP1 and LMP2 without EBNA2 mRNAs the viral gene expression 
in NK/T lymphoma cells is type II (Chiang et al., 1996b; Minarovits et al., 1994). 
 
Extranodal NK/T cell lymphomas are observed to be high inflammatory infiltrative and 
these infiltrating cells could be actively recruited by the cancer cells to support their 
survival and proliferation.  
 
1.4.4 Nasopharyngeal carcinoma 
NPC was the first discovered EBV carrying epithelial tumor (zur Hausen et al., 1970). 
According to World Health Organization classification based on the degree of 
differentiation NPC can be grouped into three types: the keratinizing squamous cell 
carcinoma (type I), the non-keratinizing carcinoma (type II) and the undifferentiated 
carcinoma (type III). EBV is observed in almost all type III NPCs from endemic 
regions but is absent in type I NPCs found in non-endemic regions (Yu and Yuan, 
2002). 
 
In undifferentiated NPC cells the EBV gene expression was found to be type II (Brooks 
et al., 1992; Busson et al., 1992; Fahraeus et al., 1988b; Young et al., 1988). According 
to IHC studies, despite EBV is present in all the undifferentiated NPCs LMP1 
expression ranges from 20-60% (Tao et al., 2006). The lack of LMP1 expression in 
EBV positive NPCs could be due to the CpG methylation of the LMP1 promoter (Hu et 
al., 1991) 
 
Based on previous findings, it was proposed that EBV infection occur in an genetically 
altered nasopharyngeal epithelial cell which might favor the establishment of a latent 
EBV infection and the EBV latent genes expressed thereafter might contribute to the 
 16 
survival and proliferation of the malignant clone (Chan et al., 2000; Lo et al., 1995; 
Pathmanathan et al., 1995; Raab-Traub and Flynn, 1986; Tsao et al., 2002).  
 
1.4.5 Post transplant lymphoproliferative disorders 
Post-transplant lymphoproliferative disorders (PTLDs) are B cell lymphoproliferations 
developed due to immunosuppression in recipients of solid organ, bone marrow (BM) 
or hematopoietic stem cell (HSC) allograft (Tsao and Hsi, 2007). EBV is the most 
important risk factor for EBV-driven PTLD in EBV seronegative recipients. PTLD 
comprises four subtypes: the early PTLD lesions, the polymorphic PTLDs (P-PTLDs), 
the monomorphic PTLDs (M-PTLDs) and the cHL type PTLD.  
 
Early PTLD lesions normally occur within the first two years after transplantation in 
the lymph nodes or oropharynx. They are almost always polyclonal and contain 
multiple EBV infection. In these cells EBV gene expression is type III. Reduction of 
immunosuppression often leads to regression of the early lesions (Tsao and Hsi, 2007). 
 
P-PTLDs develop mostly in extranodal sites with detectable chromosomal 
abnormalities (Poirel et al., 2005). EBV gene expression in this type is type III. About 
half of P-PTLDs regress with reduction of immunosuppression (Chadburn et al., 1998; 
Curtis et al., 1999). 
 
M-PTLDs are similar to B cell lymphomas. These cells are monoclonal transformed B 
lymphocytic or plasmacytic proliferations. In this type of PTLD EBV gene expression 
can be type I, type II or type III (Tsao and Hsi, 2007).   
 
cHL PTLD normally occur in renal transplant patients and is always EBV positive. 
EBV gene expression in cHL PTLD is type II. 
 
It is important to note that about 20~30% PTLDs are EBV negative and they normally 
occur late after transplantation (Harris et al., 1994; Leblond et al., 1998). 
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Table 2. EBV positivity in EBV associated malignancies 
EBV associated malignancies EBV positivity 
 
Lymphoid tissues  
Burkitt’s lymphoma, endemic                        98% 
Burkitt’s lymphoma, sporadic                        ~30% 
AIDS-immunoblastic lymphoma                60% 
AIDS-immunoblastic lymphoma-in CNS                                                     100% 
Post-transplant lymphoma                       >70% 
Hodgkin’s lymphoma                                     50% 
T-cell lymphomas                                     10-30% 
Lethal midline granuloma                           >90% 
Diffuse large B cell lymphoma                    8~10% 
NK/T cell lymphoma 100% 
Epithelial tissues  
Gastric carcinoma ~10% 
Undifferentiated nasopharyngeal carcinoma 100% 
 
 
1.4.6 EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly 
Diffuse large B-cell lymphomas (DLBCLs), the most common group of malignant 
lymphomas, account for 30% of adult non-Hodgkin lymphomas (NHLs) and represent 
a heterogeneous group of tumors with regard to morphologic, phenotypic, molecular, 
clinical course and response to therapy (Harris et al., 1994).  
 
Based on criteria such as immunophenotype, morphology, viral association [e.g. 
Epstein - Barr virus (EBV) or HHV8] or underlying genetic abnormalities, DLBCL can 
be divided into subgroups. 
 
EBV-positive DLBCL of the elderly, also known as age-related EBV-positive B-cell 
lymphoproliferative disorder or senile EBV-associated B-cell lymphoproliferative 
disorder, was initially described in 2003 by a Japanese group (Oyama et al., 2003). It is 
defined as a clonal EBV carrying B-cell proliferation. Despite of the report of a few 
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younger cases, majority of the EBV-positive DLBCL patients were older than 50 years. 
The clinical course of EBV-positive DLBCL patients is characterized by a short 
survival rate of about 24 months. The incidence of EBV positivity in DLBCL patients 
of Asian or Latin American origin ranges from 9%-15% (Morales et al., 2010; Oyama 
et al., 2007; Park et al., 2007b). However, in western countries this incidence is only 
less than 5% (Gibson and Hsi, 2009; Hoeller et al., 2010). 
 
Both type II and type III EBV gene expression pattern were observed in EBV-positive 
DLBCL patients. Among EBERs positive DLBCL cells by ISH, LMP1 has been found 
to be positive in 94% of the cells whereas EBNA2 expression was observed in only 
28% of the cells (Oyama et al., 2007; Shimoyama et al., 2006; Shimoyama et al., 2008) 
(!!! INVALID CITATION !!!). It has been proposed that LMP1 induced NK-κB 
pathway activation might contribute to the survival of EBV-positive DLBCL cells 
(Berger et al., 1997). LMP1 expression was demonstrated to be the most important 
poor prognostic indicator associated with the shortest survival rate (21 months) when 
compared to other molecular markers such as survivin, VEGF-A and VEGF-C (Paydas 
et al., 2009). 
 
Despite EBV-positive DLBCL is not related to any known immunodeficiency states, it 
is possible that other unknown immunosuppressive factors or conditions could play a 
role in the pathogenesis of this type of lymphoma.  
 
The currently available data indicated that the survival rate of EBV-positive DLBCL is 
worse than the EBV-negative DLBCL. In a Japanese study which evaluated 1792 
DLBCL patients and compared 96 EBV positive cases with EBV negative ones, EBV-
positive DLBCL patients showed a shorter survival rate than EBV-negative patients 
(Oyama et al., 2007). A Korean study reported that upon chemotherapy and 
chemoimmunotherapy, EBV-positive DLBCL cases were associated with a worse 
overall survival and a worse progression-free survival compared to EBV-negative 
DLBCLs (Park et al., 2007b). In a similar study based on Peruvian DLBCL patients 
treated with chemotherapy alone, EBV-positive DLBCL patients showed a significant 
shorter overall survival compare to EBV-negative cases (7 versus 47 months; 
p=0.01)(Morales et al., 2010). A recent study on eight European EBV-positive DLBCL 
patients showed that they had poor survival rate than EBV-negative patients (Hoeller et 
al., 2010). On the basis of available data, EBV-positive DLBCL patients showed a 
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worse response to chemotherapy than their EBV-negative counterparts (Oyama et al., 
2007; Park et al., 2007b; Yoshino et al., 2006). 
 
So far, there is no widely accepted treatment for EBV-positive DLBCL beyond the 
current standard therapy for DLBCL. There are several ongoing clinical trials focused 
on treating relapsed/refractory EBV-positive lymphomas in immunocompetent patients 
with EBV-specific cytotoxic T cells, the combination of ganciclovir or valganciclovir 
and arginine butyrate, and the combination of bortezomib and ganciclovir. It seems that 
other novel therapies based on new strategies are needed given the aggressive clinical 
course and poor outcomes of EBV-positive DLBCL.  
 
1.5 The impact of microenvironment on B-lymphocytes and their malignancies 
1.5.1 Tumor microenvironment general introduction 
The microenvironment represents the compilation of accessory cells that within 
individual organs work as a team through cell-cell contacts and active molecular 
crosstalk to provide functional scaffolding to parenchymal cells. In solid tumors, the 
microenvironment is instrumental to the survival and proliferation of cancer cells. It is 
built up by the concurrence of inflammatory cells that produce growth factors, new 
vessel formation that provides nutrients, and immune tolerance that avoids immune-
mediated elimination (Burger et al., 2009). Signals from the tumor microenvironment 
are a major hurdle in cancer treatment, and the neoangiogenetic component in tumor 
microenvironment has become an attractive target for treatment strategies (Albini and 
Sporn, 2007).
 
 
The development of blood cancers requires specialized tissue microenvironments, such 
as bone marrow and secondary lymphoid organs. These microenvironments are 
composed of different populations of accessory stromal and T cells that interact with 
cancer cells and contribute to tumor growth and drug resistance (Burger and Kipps, 
2002; Caligaris-Cappio, 2003). Blood cancer cells differ in their dependency on signals 
from the microenvironment (Burger et al., 2009).  
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Figure 5. Molecular crosstalk between malignant B cells, exemplified for CLL B 
cells, and the microenvironment. (Adapted from Burger et al., Blood, 2009) 
Nurselike cells (NLC), Mesenchymal stromal cell (MSC), Lymphoma-associated macrophage 
(LAM) 
 
 
1.5.2 Microenvironment in blood cancers
 
The microenvironment in blood malignancies can be grouped into three major patterns 
(Burger et al., 2009).  
 
The first pattern is described as loss of interconnection with the microenvironmental 
network. This occurs when a genetic change provides the cancer cells with a sustained 
proliferation advantage that is autonomous and independent of the support of the 
microenvironment. Burkitt lymphoma is a typical example, where all malignant B cells 
are determined to proliferate due to c-myc translocation. Therefore, in Burkitt 
lymphoma, the microenvironment tents to have a minor role in the survival and 
proliferation of the neoplastic cells.  
 
The second pattern is characterized by the phenomenon that the cancer cells engage in 
deregulated interactions with the supportive stroma that provide the malignant cells 
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with growth- and drug-resistance signals. The acute leukemias are a typical example 
that the leukemia stem cells (LSCs) escape the tightly regulated cell growth- and 
proliferation-control within the hematopoietic niches, parasitizing in the supportive 
hematopoieic microenvironment. In this pattern, the dependency of the cancer cells on 
the stromal for growth and survival is partially retained and may lead to the survival of 
clones obtained a higher affinity for the microenvironment (Burger and Burkle, 2007; 
Burger and Peled, 2009).  
 
The third pattern describes a regulated coexistence of the malignant cells and the 
microenvironment in B-cell tumors, such as chronic lymphocytic leukemia (CLL), 
follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphomas, 
and multiple myeloma (MM). The interactions between the malignant cells and the 
microenvironment in this pattern resemble the situation that the normal counterpart B 
cells engage in with their respective microenvironments. Therefore, the proliferative 
drive for the malignant cells is highly dependent on external signals from the 
microenvironment, such as antigens, cytokines, and cell-cell interactions.  
 
1.5.3 Cytokine general introduction 
Cytokines are small proteins that are secreted by cells throughout the body. They are a 
category of signaling molecules used extensively in intercellular communication. 
Cytokines can be classified as proteins, peptides, or glycoproteins; the term "cytokine" 
comprises a large and diverse family of molecules produced by cells of diverse origin. 
Based on their presumed function, cell of secretion, or target of action cytokines have 
been classed as lymphokines, interleukins, and chemokines.  
 
Through cytokine specific surface receptors the signal is transmitted from the outside to 
the inside of a cell. One cytokine can activate several signaling pathways regulating a 
number of biological functions (Kotenko and Pestka, 2000). 
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1.5.4 Chemokines and their receptors  
1.5.4.1 General introduction 
The term chemokine refers to a specific class of cytokines that mediates chemotaxis 
between cells. The chemokine family is composed of ~40 chemotactic cytokines (Kim, 
2005; Kim and Broxmeyer, 1999). Most chemokines are soluble proteins with an 
average ~100 amino acid residues. Chemokines exist in two forms In vivo: soluble 
(induce chemotaxis) and surface bound (induce haptotaxis) (Kim, 2005). Chemokines 
play important roles in cell migration, inflammation, haematopoiesis, lymphoid 
structure formation, tumor growth and several other pathological conditions  (Raman et 
al., 2007).  
 
Chemokines function by activating specific chemokine receptors, which results in the 
migration of cells to the appropriate tissues or compartments within tissues and other 
functions. Chemokine receptors are G protein-coupled receptors containing 7 
transmembrane domains that are found on the surface of leukocytes. They have been 
divided into four families depending on the type of chemokine they bind; CXCR that 
bind CXC chemokines, CCR that bind CC chemokines, CX3CR1 that binds the sole 
CX3C chemokine (CX3CL1), and XCR1 that binds the two XC chemokines (XCL1 
and XCL2) (Guerreiro et al., 2011). 
 
1.5.4.2 The role of chemokines and their receptors in lymphoid structure 
formation  
Homeostatic chemokines such as CXCL12 (the ligand of CXCR4), CXCL13 (the 
ligand of CXCR5), CCL19 and CCL21 (the ligands of CCR7) are involved in 
lymphoid structure formation. CXCL13 is necessary to form certain lymph nodes 
(Ansel et al., 2000), and expression of this chemokine induces formation of ectopic 
lymphoid structures (Luther et al., 2003). CD45+CD4+CD3- lymphoid tissue inducer 
cells express CXCR5 and CCR7 and migrate toward lymphoid stromal precursor cells 
during embryo development (Cupedo and Mebius, 2005). Lymphoid stromal precursor 
cells express CXCL13, CCL19, and CCL21 and adhesion molecules upon stimulation 
with tumor necrosis factor family cytokines (Dejardin et al., 2002; Muller and 
Siebenlist, 2003; Ngo et al., 1999). The interaction between lymphoid tissue inducer 
cells with lymph node organizers induces the production of appropriate chemokine 
signals that amplify the formation of lymphoid structures. 
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Figure 6. The greater chemotactic network and various modes of lymphocyte 
migration. (Adapted from Kim, Current Opinion in Hematology, 2005)The 
diagram on the left depicts the greater chemotactic network that is composed of 
chemokines (~40 members), lipid chemoattractants, antimicrobial peptides, pathogen-
derived products, neurotransmitters, complement products, and cytokines. The 
chemoattractants that can regulate homeostatic lymphocyte migration are underlined. 
On the right, various modes of immune cell migration are depicted. Chemotaxis is cell 
migration up a chemoattractant gradient. Many chemoattractants induce chemotaxis 
through G protein-coupled seven-transmembrane domain receptors (GPCRs). It has 
been reported that some chemoattractants can induce reverse chemotaxis (called 
‘chemofugetaxis’) at high concentrations, which is cell migration down the gradient. In 
vivo, many chemoattractants are presented on cells or extracellular matrix, forming 
surface-bound chemotactic signals. Cell migration to the surface-bound 
chemoattractants is called ‘haptotaxis’. Once migrated to or through the surface 
chemotactic layer, immune cells may be pushed away from the surface-bound 
chemoattractants, a process called ‘haptorepulsion’. Chemokinesis refers to random cell 
migration even in the absence of any chemoattractant gradient. EDN, eosinophil-
derived neurotoxin; fMLP, fMet-Leu-Phe; IL16, interleukin-16; LPA, lysophosphatidic 
acid; LTB4, leukotriene B4; PGD2, prostaglandin D2, SCF, stem cell factor; S1P, 
sphingosine 1-phosphate. 
 
 
1.5.4.3 The role of chemokines and their receptors in the migration of B 
lymphocyte to secondary lymphoid tissues 
B cells migrate to secondary lymphoid tissues by expression of CCR7. CXCR5-
positive B cells localize in the B-cell area expressing the CXCR5 ligand CXCL13. 
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Germinal centers are polarized so that they have a dark zone and a light zone. In mice, 
the germinal center polarity is regulated by CXCL12, together with CXCL13 (Allen et 
al., 2004). B cells proliferate and undergo SHM in the dark zone and migrate to the 
light zone for antigen-dependent B-cell selection. CXCL12 was observed to be more 
intensely expressed in the dark zone than in the light zone, keeping centroblast B cells 
in the dark zone (Allen et al., 2004). CXCR5-positive GC Th cells and follicular 
stromal cells produce the B-cell zone chemokine CXCL13 themselves to recruit 
CXCR5-positive B cells, T cells, and dendritic cells to expand germinal centers (Kim et 
al., 2004).  
 
1.5.4.4 The role of chemokines and their receptors in the migration of neoplastic B 
cells 
Chemokines and their receptors can be critical for B-lymphoma cells homing to the 
supporting cells, and for the dissemination of malignant B cells. The neoplastic B cells 
express high levels of CXCR4 and CXCR5 in ML (Mantle cell lymphoma) (Kurtova et 
al., 2009). Similarly, high levels of CXCR4, CXCR5 and CCR7 have been observed in 
DLBCL of the central nervous system (Jahnke et al., 2005). ML may further 
disseminate through the lymphoid tissue via CXCR4 and CXCR5 as stromal cells 
constitutively secrete CXCL12 and CXCL13 molecules. CXCL13 is secreted by the 
neoplastic B cells in FL, which also express CXCR4 and CXCR5 (Husson et al., 2002). 
CXCL13 production in tumor microenvironment may lead to an accumulation of 
neoplastic cells (Smith et al., 2003). CXCL13 secretion by lymphoma cells can recruit 
CXCR5-positive cells to create a supportive tumor microenvironment. CXCR4-
CXCL12 signaling pathway was shown to be involved in both tumor vasculature 
development and the growth and metastasis of CXCR4 expressing tumors (Raman et 
al., 2007; Salcedo and Oppenheim, 2003). CCR7 expression was reported to be 
associated with cancer metastases (Moore, 2001).  
 
1.5.4.5 EBV regulated chemotactic responses  
EBV has been shown to play a role in the modulation of chemokine receptor expression 
and the receptor mediated cell migration. In the B lymphoma line BJAB, CXCR4 was 
downregulated by LMP1 or EBNA2 (Nakayama et al., 2002). Similarly, EBNA4 was 
shown to downregulated CXCR4 expression on LCLs (Chen et al., 2006). On the other 
hand, primary EBV infection of tonsillar B cells with expression of EBNA2 and LMP1 
led to reduction in the expression of CXCR4 and the receptor mediated chemotaxis 
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(Ehlin-Henriksson et al., 2006). In the EBV negative Burkitt lymphoma line BL41 
CCR7 was upregulated by EBNA2 (Burgstahler et al., 1995). Modulation of 
chemotactic responses of the EBV carrying cells may serve the viral strategy by 
directing the host cells into certain microenvironments, favoring the differentiation or 
survival and proliferation of the cells.  
 
1.5.5 EBV latent gene regulation by interleukins 
Interleukins (ILs) play important roles in intercellular signals in inflammation, 
immunity against cancer and endothelial cell biology. Some of them showed 
therapeutic potential in cancer treatment e.g. IL-2, IL-4 and IL-21 (Margolin, 2008). 
Here, I review some of the ILs that have been shown to modulated EBV gene 
expression in EBV carrying B cells. 
 
1.5.5.1 IL-10 
IL-10 is classified as a class-2 cytokine, a set of cytokines including IL-19, IL-20, IL-
22, IL-24, IL-26, interferons and interferon-like molecules (Pestka et al., 2004). It is 
primarily produced by monocytes and, to a lesser extent, type 2 T helper cells (TH2), 
mastocytes, CD4+CD25+Foxp3+ regulatory T cells, and in a certain subset of activated 
T cells and B cells. Both human and viral IL-10 can be found in EBV-carrying 
supernatants (Sairenji et al., 1998). IL-10 was found to induce LMP1 expression in type 
I and Wp-restricted BL lines, in the conditional LCL line ER/EB2-5 where EBNA2 
was downregulated in the absence of estrogen, in tonsillar B cells infected with 
EBNA2-deficient EBV strain, and in EBV-positive NK lymphoma lines (Kis et al., 
2006). 
 
1.5.5.2 IL-4 and IL-13 
IL-4 is produced by the Th2 subset of CD4 cells that have a predominantly suppressive 
effect on cellular immune functions. It shares with IL-2 and several cytokines the 
common γ receptor chain (γc) that mediates intracellular signal transduction via Janus 
kinase 3 (JAK3) and signal transducer and activator of transcription 6 (STAT6) (Wang 
et al., 2004).  
 
IL-13 is often discussed together with IL-4 because of the overlap in their receptor 
structures, cells of origin, target cells and immunologic functions. Intracellular 
signaling of IL-13 differs from IL-4 due to their difference in ligands and receptor 
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chains but both cases eventually lead to transcriptional signals through STAT6 
(Hebenstreit et al., 2006). 
 
IL-4 was shown to induce LMP1 expression independent of EBNA2 in EBV-infected 
subline of Hodgkin lymphoma derived cell line, KMH2-EBV (Kis et al., 2005). Later, 
both IL-4 and IL-13 were shown to be able to induce LMP1 expression in the absence 
of EBNA2 expression as they are able to induce the expression of STAT6 which in turn 
bind directly to the LMP1 promoter with high affinity (Kis et al., 2011). 
 
1.5.5.3 IL-21 
IL-21 is another cytokine that signals in part through the γc chain on target cells and 
shares certain properties with IL-4 in stimulating many T cell functions that have been 
investigated for their role in tumor immunotherapy. IL-21 is produced mainly by CD4+ 
T cells and NKT cells, and its targets include T, NK, B and myeloid cells, with 
signaling through JAK and STAT molecules that include STATs 1, 3 and 5 (Margolin, 
2008). IL-21 can induce Blimp1 expression through the activation of STAT3 (Calame, 
2008; Klein and Dalla-Favera, 2008).  
 
IL-21 is currently under clinical trial and demonstrated safety and achievement of 
immunological end points, moving from Phase I safety and dosing studies to Phase II 
trials for selected malignancies including non-Hodgkin’s B cell lymphoma (Andorsky 
and Timmerman, 2008).  
 
In type I BL cell lines and in the conditional LCL ER/EB2-5, IL-21 potently activated 
STAT3 and induced the expression of LMP1, but not EBNA-2, indicating that IL-21 
might be involved in the EBNA-2-independent expression of LMP1 in EBV-carrying 
type II cells in vivo, whereas in the type III LCLs and BL lines, IL-21 upregulated the 
expression of LMP1 mRNAs and repressed the C-promoter-derived and LMP2A 
mRNAs (Kis et al., 2010b). 
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2 AIMS OF THE THESIS 
The primary aims of our work were to: 
-study the EBV induced modulation of chemotactic response in primary B cells, 
-study the effect of cytokines in the chemotaxis of EBV-positive DLBCL, 
-study the role of cytokines in the modulation of EBV latent gene expression in EBV 
carrying cells, 
-study the role of EBV in EBV-positive DLBCL cells.  
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3 MATERIALS AND METHODS 
I summarized here the background information about the five DLBCL cell lines that we 
used in our study in a table. Additionally, I think it would be helpful to illustrate the 
mechanism how EBV is knocked out from the EBV positive cell line by dnEBNA1 
used in our experiment with a schematic drawing.  
 
 
Figure 7. Primary structure of dnEBNA1. 
 
 
 
 
 
 
 
 
 
 
 
   29 
A                                                               B                                    
 
C                                                               D 
 
 
 
Figure 8. The mechanism how dn-EBNA1 knocks out EBV from an EBV carrying 
cell. A) EBV episome is tethered to the chromosome by wild-type EBNA1. After transfection the 
tet-off-dn-EBNA1 plasmid is present. In the presence of Dox, dnEBNA1 expression is switched off. 
B) When Dox is washed out from the medium dnEBNA1 expression is switched on. C) With the 
accumulation of dnEBNA1 the connection between EBV and the chromosome is blocked as 
dnEBNA1 can compete for the OriP binding site with wild-type EBNA1. D) Finally, EBV episome 
is lost gradually during proliferation. 
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Table 3. DLBCL Cell line background information 
Name EBV gene expression Translocation References 
Farage not reported  
 
not reported  
 
(Shubinsky et al., 1993) 
(Shubinsky and Schlesinger, 
1994) 
Val  The DBLCL tumor 
was EBV-negative by 
EBER-ISH (personal 
communication) 
 
The cell line was 
EBV+ by PCR 
BCL2 
C-MYC 
BCL6  
 
(Kerckaert et al., 1993) 
(Dallery et al., 1995) 
(Dyer et al., 1996) 
(Bonnefoy-Berard et al., 
1994) 
 
OPL2 EBV integrated, no 
Wp or Cp, Qp-
positive, LMP-1 
negative 
 
not reported  
 
(Takakuwa et al., 2006) 
DOHH2 The cell line was EBV-
negative by ACIF 
staining 
 
BCL2 
C-MYC 
 
(Kluin-Nelemans et al., 
1991) 
 
Ocily19 Maybe EBV-positive 
(personal 
communication) 
not reported  
 
(Chang et al., 1995) 
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4 RESULTS AND THEIR POTENTIAL IMPLICATIONS 
 
A) STUDIES ON THE ROLE OF EBV IN EBV-POSITIVE DLBCL (PAPER IV) 
The role of EBV in EBV carrying malignant cells has been studied by using dnEBNA1 
(Imai et al., 2005; Kang et al., 2011; Kennedy et al., 2003; Nasimuzzaman et al., 2005; 
Watanabe et al., 2010). In EBV+ BLs, the role of EBV has been clarified and EBV was 
proven to provide survival factors by blocking apoptosis and induction of proliferation 
(Kennedy et al., 2003; Watanabe et al., 2010; Vereide and Sugden, 2009).  
 
To study the role of EBV in EBV-positive DLBCL we started our work with DLBCL 
cell line characterization. We have collected and characterized five DLBCL cell lines 
(Farage, Val, DOHH2, OPL2 and Ocily19) that have been considered as EBV positive 
in previous studies and examined their EBV latent gene expression pattern and the 
expression of genes associated with GC progression or GC/post GC phenotype (Paper 
IV). 
 
Among these five DLBCL lines, we found both type II and type III phenotypes. Farage 
has a type III EBV gene expression whereas Val shows a type II expression. In OPL2, 
EBV is integrated (Takakuwa et al., 2006) which may explain why it is EBNA1 
negative but EBNA2 and LMP1 positive. DOHH2 was reportedly EBV negative 
(Kluin-Nelemans et al., 1991) but our results show that it is a type III EBV carrier. The 
results on EBV gene expression patterns are in line with published data on EBV status 
of DLBCL tumors. (Adam et al., 2011; Kuze et al., 2000; Oyama et al., 2003; Oyama et 
al., 2007; Park et al., 2007a; Shimoyama et al., 2006; Shimoyama et al., 2008)  
 
Since DLBCL can be subdivided into three subgroups, GC derived, ABC derived or 
other (Alizadeh et al., 2000; Hans et al., 2004), we have also studied the expression of 
B cell differentiation related genes such as BCL6, IRF4 and Blimp1. Farage was found 
to express high level of BCL6, indicating a GC origin. It also expressed the BCL6 
repressor, IRF4 and BCL2 which is normally not expressed in GC B cells. The 
expression of BCL2 and BCL6 can be seen in Val and DOHH2 as well, but the level of 
expression is higher. Ocily19 was BCL6 positive, indicating a GC origin. Interestingly, 
this line also expressed moderate level of Blimp1, a plasma differentiation marker. 
Blimp1 expression can be observed in DOHH2 as well. OPL2 is BCL6 negative and 
strongly Blimp1 positive, indicating a plasmatoid phenotype. In conclusion, Farage, 
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Val, DOHH2 and Ocily19 have a GC phenotype whereas OPL2 has an atypical ABC 
phenotype that PAX5 and Blimp1 are both expressed in the same cells.    
 
Using dnEBNA1, we knocked out EBV from EBV positive DLBCL line, Farage, to 
investigate the role of EBV in EBV positive DLBCL. We found that downregulation of 
EBV encoded genes is followed by induction of apoptosis. Furthermore, cell growth 
was inhibited in the cells indicating that EBV sustains the growth of EBV positive 
DLBCLs. Since small molecules e.g. Roscovitine targeting EBNA1 to knock out EBV 
from EBV carrying cells were screened out recently (Kang et al., 2011), we then 
performed Roscovitine treatment on the EBV-positive DLBCL lines. Roscovitine was 
found to downregulated EBNA1 in EBV positive DLBCL lines, Val and DOHH2. 
Following the downregulation of EBNA1, decreased cell growth could be observed in 
the EBV positive DLBCL lines, Val and DOHH2 at a dose that the growth of EBV 
integrated DLBCL line, OPL2 and EBV negative B cell line, BJAB was not blocked. 
Interestingly, 12 days Roscovitine treatment significantly inhibited cell growth of 
Farage whereas EBNA1 expression in the surviving cells was highly expressed. This 
could be due to that the survival of Farage cells are highly dependent on EBV and the 
strong EBNA1 function inhibition effect of Roscovitine might kill most of the EBV 
losing Farage which might select out those EBNA1 strong positive cells. Given the fact 
that EBV positive DLBCL patients showed a poorer treatment response and inferior 
prognosis compared with EBV negative cases (Adam et al., 2011; Kuze et al., 2000; 
Oyama et al., 2003; Oyama et al., 2007; Park et al., 2007a; Shimoyama et al., 2006; 
Shimoyama et al., 2008), alternative therapies need to be developed in patients with 
EBV positive DLBCL. Our findings show the possibility of clinical implication of 
small molecules targeting EBV e.g. Roscovitine in DLBCL treatment in the future.  
 
B) THE ROLE OF CYTOKINES IN EBV-POSITIVE DLBCL LINES (PAPERS 
III, IV) 
As IL-4 and IL-21 have been shown to induce LMP1 expression in B cell derived cell 
lines originating from EBV positive BL, HL and LCL (Kis et al., 2011; Kis et al., 2005; 
Kis et al., 2010a) we investigated the role of these cytokines in the EBV-positive 
DLBCL lines (Paper IV). We found that LMP1 expression is upregulated in the EBV 
positive DLBCL lines by either IL-4 or IL-21. Due to the high level of LMP1 induction 
by IL-4 and IL-21, we continued our experiment with the type III DLBCL cell line, 
Farage. IL-4 upregulated LMP1 expression but did not change EBNA1 and EBNA2 
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expression. In contrast, IL-21 upregulated LMP1 but downregulated both EBNA1 and 
EBNA2 which is consistent with effect of IL-21 on LCLs (Kis et al., 2010a). Kinetic 
experiment on Farage showed that the effect of IL-4 and IL-21 was not transient. IL-21 
can induce human B cell activation, differentiation and proliferation. (Ettinger et al., 
2008) In both IL-4 and IL-21 treated Farage cells, LMP1 upregulation was followed by 
an elevated level of IRF4 and downregulation of BCL6. Previously, EBNA2 was 
shown to upregulate IRF4 in EREB2.5 cells. (Spender et al., 2006) Conversely, in the 
present study, IRF4 expression was increased despite of downregulation of EBNA2 in 
the IL-21 treated Farage. This induction of IRF4 can be due to the activation of NF-κ
B pathways by LMP1, a CD40 mimicker (Ettinger et al., 2008; Saito et al., 2007; Teng 
et al., 2007). IRF4 was shown to bind to the BCL6 promoter and inhibit its expression 
(Teng et al., 2007). It may be conjectured that IL-4 and IL-21 induced LMP1 could be 
responsible for the upregulation of IRF4 and the downregulation of BCL6 expression. 
Blimp1, the master regulator of PC differentiation (Martins and Calame, 2008) was 
reported to  be downregulated by LMP1 in GC B cells (Vrzalikova et al., 2011). 
However, although LMP1 was upregulated by IL-21 in Farage Blimp1 expression was 
found to be elevated. Blimp1 can be induced in Farage by IL-21 via activation of 
STAT3 (Diehl et al., 2008; Ettinger et al., 2005). The induction of Blimp1 by IL-21 in 
the Farage cells indicated differentiation towards plasma cell phenotype.  
 
Recently, IL-21 was found to induce apoptosis in DLBCL (Sarosiek et al., 2010). This 
was attributed to the activation of the STAT3-c-Myc signaling pathway, leading to 
downregulation of Bcl-2 and Bcl-XL and the upregulation of Bax (Sarosiek et al., 
2010). In view of this finding, IL-21 is being considered as a possible therapeutic agent 
for DLBCL (Andorsky and Timmerman, 2008; Sarosiek et al., 2010). However, 
although nine DLBCL lines have been tested for IL-21 sensitivity, their EBV carrying 
status was not determined. Given that the clinical features of the EBV-positive DLBCL 
differ from the EBV-negative ones with regard to prognosis and therapeutic response 
(Kuze et al., 2000; Oyama et al., 2003; Oyama et al., 2007; Park et al., 2007a; 
Shimoyama et al., 2006; Shimoyama et al., 2008) we then examined the IL-21 
sensitivity on EBV positive DLBCL lines (Paper III) and found that IL-21 did not 
induce apoptosis but, on the contrary, stimulated the proliferation of Farage cells, in 
spite of the demonstrated IL-21 receptor mediated STAT3 phosphorylation and 
concomitant c-Myc upregulation. We also found that expression of dnEBNA1 and the 
consecutive downregulation of EBV gene expression antagonized the IL-21 induced 
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proliferation of Farage and increased apoptosis. The fact that the downregulation of 
EBV gene expression by dnEBNA1 counteracted IL-21 induced proliferation and 
increased apoptosis suggests that EBV contributes to the IL-21 induced proliferation in 
EBV positive DLBCL line. The IL-21 upregulated LMP1 may counteract the STAT3-
c-Myc mediated apoptosis in IL-21 treated Farage cells, due to its ability to raise the 
expression of the anti-apoptotic protein, Bcl-2, in B cells (Rowe et al., 1994). CD40 
that is mimicked by LMP1 was reported to induce proliferation in IL-21 treated B cells 
and to prevent the inhibitory effect by IL-21 in LPS-activated B cells (Jin et al., 2004).  
Additionally, LMP1 is able to activate both the classical and non-classical NF-κB 
pathways. The ability of LMP1 to activate NF-κB pathways might be relevant to the 
IL-21 induced proliferation in Farage as well (Eliopoulos et al., 2003; Huen et al., 
1995). Our findings indicated the importance of investigating the EBV carrying status 
of DLBCLs prior to therapeutic exposure to IL-21. 
 
C) STUDY ON THE EBV MODULATED CHEMOTAXIS IN EBV-CARRYING 
B CELLS (PAPERS I, IV)  
This work is a continuation of our previous study showing that the CXCR4 mediated 
chemotaxis can be negatively regulated upon EBV infection in the primary tonsillar B 
cells (Ehlin-Henriksson et al., 2006). In this study, we continued our study on CXCR5 
and CCR7 mediated chemotaxis after EBV infection of tonsillar B cells (Paper I). We 
found that both the expression of these two chemokine receptors and the receptor 
mediated chemotactic responses were downregulated after EBV infection. We also 
found that CCR7 expression on EBV-infected peripheral B cells showed a slower 
decrease in cell surface expression over time compared with tonsillar B cells, which 
may suggest that CCR7 expression is differently regulated in B cells depending on 
origin and cellular background. The chemokine receptors CXCR5 and CCR7 play an 
essential role in B-cell trafficking in lymphoid tissue (Muller et al., 2003; Okada et al., 
2002) and for microanatomic organization of lymphoid tissue. CXCR5–CXCL13 
interactions direct the activated B cells into the follicle and CCR7–CCL21 guide the 
cell to the B-cell-T-cell border. CXCR5, together with CXCR4, is involved in the GC 
dark and light zone organization (Allen et al., 2004). Consequently, reduced expression 
of the CXCR5 and CCR7 chemokine receptors in the EBV-infected tonsillar B cells 
may interfere with the migration of the infected cell. Our findings suggest a model that 
primary EBV infection of tonsillar B cells leads to a reduced chemotaxis mediated by 
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CCR7 and CXCR5, as well as to altered expression of several chemokine receptors and 
chemokines and as a consequence, the EBV infected B cell may be excluded from the 
B-cell follicles and will be retained in the interfollicular areas of the tonsil. 
 
In the B lymphoma line BJAB, CXCR4 was downregulated by LMP1 or EBNA2 
(Nakayama et al., 2002). In contrast CCR7 was upregulated by EBNA2 in the EBV 
negative Burkitt lymphoma line BL41 (Burgstahler et al., 1995). On the other hand, our 
work showed that primary EBV infection of tonsillar B cells with expression of 
EBNA2 and LMP1 led to reduction in the expression of CXCR4 and CCR7 (Ehlin-
Henriksson et al., 2009; Ehlin-Henriksson et al., 2006). Based on the above studies and 
our findings that IL-21 and IL-4 can modulate EBV latent gene expression in DLBCL 
cells, we studied whether and how chemotaxis can be modulated by IL-21 or IL-4 
stimulation in EBV positive DLBCL cells (Paper IV). We first performed studies on 
Val and Farage in which LMP1 was highly induced after IL-21 and IL-4 treatment. Val 
expressed CXCR4 and CCR7. No major change was seen in CXCR4 expression after 
IL-21 and IL-4 treatment but both cytokines decreased CCR7 expression. Farage 
expressed low the levels of CCR7 and CXCR4 expression. After IL-21 stimulation 
CCR7 and CXCR4 were highly induced whereas IL-4 induced CCR7 but no change of 
CXCR4 expression. To investigate whether the induced chemokine receptors 
expression results in a higher chemotactic response we next performed transwell assays 
after IL-21 and IL-4 stimulation of Farage and Val. The specific CCL21 induced 
migration of IL-21 stimulated Farage was increased about 10-fold compared with none-
treated cells whereas the chemotactic response to CXCL12 was elevated 20-fold. In 
Val, chemotactic response to CXCL12 showed a minor increase after IL-4 or IL-21 
treatment. IL-21 induced a 14-fold increase of CCL21-mediated migration compared to 
non-stimulated cells whereas the chemotactic response after IL-4 stimulation of Val 
was unchanged. In our experiments, IL-4 induced a high expression of CCR7 in Farage 
than IL-21 did. However, the increased expression was not followed by high increased 
migration as the IL-21 stimulated cells showed a much higher chemotactic response to 
CCL21. IL-21 stimulation induced a clear increase in CCL21-induced migration in 
both Val and Farage although EBNA2 expression was decreased in Farage and Val is 
EBNA2-negative. Our results showed that EBNA2 downregulation by IL-21 treatment 
of Farage may play a role in the increased CXCR4 expression and the ligand-induced 
migration. This is in line with previous report on EBNA2-induced downregulation of 
CXCR4 (Nakayama et al., 2002). Furthermore, EBNA2 was shown to induce CCR7 in 
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the BL line BL41 (Burgstahler et al., 1995). We find that CCR7 expression is increased 
by IL-4 stimulation but when EBNA2 is downregulated by IL-21 the increase of CCR7 
is lower. 
 
To investigate whether EBV knocking-down by dnEBNA1 would modulate 
chemotactic response to CXCL12 and CCL21 we downregulated EBNA1 in dn-
EBNA1-Farage by expression of dnEBNA1 and then examined chemokine receptor 
expression and cell migration upon IL-4 or IL-21 treatment. We found a decreased 
CXCL12-and CCL21-induced migration indicating that EBV may promote chemotaxis 
upon cytokine treatment. 
 
CCR7 has been implicated to be involved in nodal dissemination and CXCL12, ligand 
of CXCR4, has been shown to both promote tumor vasculature development and to 
support growth and metastasis in CXCR4+ tumors. CXCR4 is also associated with 
bone marrow involvement of nodal lymphomas (Deutsch et al., 2013). IL-21 
stimulation induces CXCR4 and CCR7 expression on Farage. The receptors are 
functional as CCL21 and CXCL12 induce migration in a Transwell assay. Plasma cells 
home to bone marrow through CXCR4-CXCL12 axis (Nagasawa et al., 1996). IL-21 
induces both increased CXCL12 mediated migration and Blimp1 expression in Farage 
which may promote plasma cell differentiation and homing to bone marrow and 
furthermore, may lead to activation of EBV lytic cycle and virus production (Laichalk 
and Thorley-Lawson, 2005).  
 
Our findings indicate that IL-21 treatment of DLBCL patients with EBV carrying 
tumors may induce migration of tumor cells, through increased CXCR4-mediated 
chemotaxis, to vascularization areas where CXCL12 level is increased thus allowing 
metastasis. Furthermore, a high CCR7-mediated chemotaxis induced by IL-21 may 
increase the nodal dissemination. 
 
D) STUDY ON THE ROLE OF TYPE I INTERFERONS IN THE 
MODULATION OF EBV LATENT GENE EXPRESSION (Paper II) 
Previously in our group we have shown that cytokines (IL-4, IL-13 and IL-21) from the 
microenvironment could induce LMP1 expression via activation of JAK/STAT 
pathways independent of EBNA2 in EBV carrying B cells (Kis et al., 2011; Kis et al., 
2010b). In this study, we investigated the role of type I IFNs in the modulation of EBV 
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latent gene expression (Paper II) as a continuation of our study on cytokine 
modulation of EBV latent genes because type I IFNs can also activate the classical 
JAK/STAT pathways (Platanias, 2005; Su and David, 2000).  
 
We found that type I IFNs strongly upregulated LMP1 protein expression in a dose-
dependent manner in the highly IFN-α-sensitive, EBV-positive BL line Daudi, while 
IFN-γ did not. Then, we investigated the LMP1-inducing effect of IFN-α on a panel of 
EBV-positive BL lines, including Daudi, Salina, and P3HR1 (lines carrying a virus 
strain that has a deletion involving EBNA2, and therefore the cells use the W-promoter 
for the transcription of the EBNAs and do not express or express only minimal amounts 
of LMPs), the type I BL lines Akata, Rael, and Jijoye-M13, the type III BL line Raji, 
and the cord blood-derived LCL CBM1-Ral-STO. IFN-α treatment resulted in the 
upregulation of LMP1 protein expression in Jijoye-M13 cells and in all the BL lines 
carrying EBNA2-deleted virus. We also found that IFN-α rapidly and specifically 
upregulates LMP1 through transcriptional activation kinetic study. 
 
The protein synthesis inhibitor cycloheximide treatment did not block IFN-α-induced 
upregulation of LMP1 but strongly enhanced it, proving that de novo protein synthesis 
is not required for the rapid induction of LMP1 by type I IFNs and LMP1 transcription 
is directly induced by type I IFN signaling.  
 
The tyrosine kinase inhibitor Piceatannol strongly inhibited LMP1 mRNA upregulation 
and specifically inhibited STAT5 phosphorylation. This finding suggests that STAT-1, 
-2, and -3 phosphorylation is not needed or is not sufficient for the direct upregulation 
of LMP1 mRNA by IFN-α, whereas STAT-5 phosphorylation may play an important 
role in it.  
 
IFN-α treatment was found to upregulate LMP1 mRNA levels in EBV infected primary 
B cells whereas EBNA2 mRNA levels were nearly equal in both the untreated and 
treated samples. Despite the upregulation of LMP1 mRNA level, the LMP1 protein 
level did not change in EBV infected primary B cells treated with IFN-α, suggesting 
inhibition of LMP1 translation. Interestingly, 24 h of IFN-α treatment moderately 
reduced LMP1 mRNA, whereas it strongly decreased LMP1 and EBNA2 protein 
levels. The downregulation of these proteins may explain the previously reported 
partial inhibition of transformation by IFN-α when added 24 h postinfection (Lotz et 
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al., 1985; Thorley-Lawson, 1981) as they play an essential role in EBV-induced B cell 
transformation.  
 
LMP1 appears to be an important link between EBV infection and systemic lupus 
erythematosus (SLE), as LMP1 induces B cells to express B cell-activating factor 
(BAFF) and a proliferation-inducing ligand (APRIL), which are mediators of B cell 
survival, T cell-independent antibody production, and immunoglobulin class switching 
(He et al., 2003). Since EBV-positive BLs originate from late germinal center B cells or 
memory B cells (Bellan et al., 2005; Thorley-Lawson and Allday, 2008), our findings 
on the LMP1-inducing effect of IFN-α in these lines and in primary B cells may 
explain the expression of LMP1 mRNA in the memory B cells of SLE patients and 
suggest a direct connection between immune dysfunction and altered regulation of 
EBV latency in SLE. However, despite its transcriptional induction in primary B cells, 
the lack of IFN-α-induced LMP1 protein calls for careful study of LMP1 protein 
expression in the memory B cells of SLE patients in the future. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Due to the clinical difference between EBV-positive and EBV-negative DLBCL, we 
initiated our study on EBV-positive DLBCL, aiming at clarifying the role of EBV in 
this subtype of DLBCL. Given the potential usefulness of IL-21 in treating DLBCL, we 
investigated the effect of IL-21 in EBV-positive DLBCL as a main focus. 
 
One of the major findings from this study is the unexpected effect of IL-21 on type III 
DLBCL cell line, Farage. Previous study described induction of apoptosis via 
activation of c-Myc and concomitant upregulation of Bax in DLBCL cells without 
checking the EBV carrying status. However, our study on type III EBV-positive 
DLBCL cells shows a completely different scenario. Based on our findings that: 
1) IL-21 upregulates LMP1 and downregulates EBNA2 expression in type III EBV-
positive DLBCL cells, 
2) IL-21 promotes plasma cell differentiation of EBV-positive DLBCL cells, 
3) IL-21 increases EBV modulated chemotaxis in EBV-positive DLBCL cells which 
may lead to spread of the tumor, 
4) IL-21 induces proliferation of type III EBV positive DLBCL cells, 
we propose a preliminary model as follows showing the scenario when the EBV-
positive type III DLBCL cells encounter IL-21stimulation from the microenvironment.   
 
IL-21 modifies EBV latent gene expression and changes cellular phenotype of type III 
EBV-positive DLBCL cells and consequently promotes cell proliferation and 
metastasis (Fig. 9). 
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Figure 9. Different effect of IL-21 in EBV-positive and EBV-negative DLBCL cells  
 
 
Of course, there are limitations in our studies. The lack of in vivo studies is the major 
one. Studies on larger number of EBV-positive DLBCL cell lines are also 
indispensable as DLBCLs are heterogeneous and EBV gene expression patterns in 
EBV-positive DLBCLs are also variable. The outcome of microenvironmental 
stimulation can be various in DLBCL cells with different EBV gene expression pattern 
and cell of origin. Additionally, our results need to be confirmed by studies on primary 
tumor cells. Consequently, this study is to be continued and reinforced in these 
directions in the future. 
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